First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1437-7772
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048 ; volume:27 ; number:12 ; day:20 ; month:10 ; year:2022 ; pages:1805-1817 ; date:12.2022
International journal of clinical oncology ; 27, Heft 12 (20.10.2022), 1805-1817, 12.2022

Urheber
Takahashi, Shunji
Oridate, Nobuhiko
Tanaka, Kaoru
Shimizu, Yasushi
Fujimoto, Yasushi
Matsumoto, Koji
Yokota, Tomoya
Yamazaki, Tomoko
Takahashi, Masanobu
Ueda, Tsutomu
Hanai, Nobuhiro
Yamaguchi, Hironori
Hara, Hiroki
Yoshizaki, Tomokazu
Yasumatsu, Ryuji
Nakayama, Masahiro
Shiga, Kiyoto
Fujii, Takashi
Mitsugi, Kenji
Takahashi, Kenichi
Nohata, Nijiro
Gumuscu, Burak
Swaby, Ramona F.
Tahara, Makato
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s10147-022-02233-6
URN
urn:nbn:de:101:1-2023020621151631276396
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 11:01 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Takahashi, Shunji
  • Oridate, Nobuhiko
  • Tanaka, Kaoru
  • Shimizu, Yasushi
  • Fujimoto, Yasushi
  • Matsumoto, Koji
  • Yokota, Tomoya
  • Yamazaki, Tomoko
  • Takahashi, Masanobu
  • Ueda, Tsutomu
  • Hanai, Nobuhiro
  • Yamaguchi, Hironori
  • Hara, Hiroki
  • Yoshizaki, Tomokazu
  • Yasumatsu, Ryuji
  • Nakayama, Masahiro
  • Shiga, Kiyoto
  • Fujii, Takashi
  • Mitsugi, Kenji
  • Takahashi, Kenichi
  • Nohata, Nijiro
  • Gumuscu, Burak
  • Swaby, Ramona F.
  • Tahara, Makato
  • SpringerLink (Online service)

Ähnliche Objekte (12)

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study

First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study

Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181

Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181

First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048

First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048

Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial

Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Pembrolizumab as first-line treatment for metastatic uveal melanoma

KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer

KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study

Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study

Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie

Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

Verbundene Objekte